U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease

FDA’s PDUFA goal date is November 1, 2026If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell ...
Scientific Research Publishing

Radiation Therapy through Genetic Profiling: A Conceptual Framework for Radiogenomic Risk Stratification and Normal-Tissue Radioprotection ()

Radiation therapy remains a central modality in cancer treatment, but normal-tissue toxicity and long-term stochastic effects ...

Agios Pharmaceuticals, Inc.: U.S. FDA Grants Priority Review to Agios' sNDA for Mitapivat in Sickle Cell Disease

FDA's PDUFA goal date is November 1, 2026If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIR ...